Axonics, Inc. Forms 3, 4 and 5: Stock Options
Statements of beneficial ownership filed with the SEC by officers, directors and 10% owners: 31 rows in 2018. Transaction codes are the SEC's. Shares and prices are split-adjusted; the as-filed figure is underneath.
- 2018-12-06: Reporting owner Pardo Geoff; Form 4; Security Stock Option (Right to Buy); Transaction A Grant, award or other acquisition pursuant to Rule 16b-3(d).
- 2018-12-06: Reporting owner Amble Erik; Form 4; Security Stock Option (Right to Buy); Transaction A Grant, award or other acquisition pursuant to Rule 16b-3(d).
- 2018-12-06: Reporting owner Tammenoms Bakker Juliet; Form 4; Security Stock Option (Right to Buy); Transaction A Grant, award or other acquisition pursuant to Rule 16b-3(d).
- 2018-12-06: Reporting owner MCNAMARA ROBERT E; Form 4; Security Stock Option (Right to Buy); Transaction A Grant, award or other acquisition pursuant to Rule 16b-3(d).
| Transaction date | Reporting owner | Form | Security | Transaction | Shares | Price | Price that day | Filing |
|---|---|---|---|---|---|---|---|---|
| 2018-12-06 | Pardo Geoff Director, 10% Owner | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +5,000 5,000 owned after | $14.80 exercise price | 2018-12-10 | |
| 2018-12-06 | Amble Erik Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +5,000 5,000 owned after | $14.80 exercise price | 2018-12-10 | |
| 2018-12-06 | Tammenoms Bakker Juliet Director, 10% Owner | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +5,000 5,000 owned after | $14.80 exercise price | 2018-12-10 | |
| 2018-12-06 | MCNAMARA ROBERT E Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +5,000 5,000 owned after | $14.80 exercise price | 2018-12-10 | |
| 2018-12-06 | Petrovich John George Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +5,000 5,000 owned after | $14.80 exercise price | 2018-12-10 | |
| 2018-12-06 | Malik Shahzad Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +5,000 5,000 owned after | $14.80 exercise price | 2018-12-10 | |
| 2018-10-30 holding as of filing | Ford Alfred J Jr Officer (Chief Commercial Officer) | 3 | Stock Option (Right to Buy) Derivative · Direct | Holding | $1.42 exercise price | 2018-10-30 | ||
| 2018-10-30 holding as of filing | Ford Alfred J Jr Officer (Chief Commercial Officer) | 3 | Stock Option (Right to Buy) Derivative · Direct | Holding | $1.63 exercise price | 2018-10-30 | ||
| 2018-10-30 holding as of filing | Jiang Guangqiang Officer (Chief Technology Officer) | 3 | Stock Option (Right to Buy) Derivative · Direct | Holding | $1.42 exercise price | 2018-10-30 | ||
| 2018-10-30 holding as of filing | Jiang Guangqiang Officer (Chief Technology Officer) | 3 | Stock Option (Right to Buy) Derivative · Direct | Holding | $1.63 exercise price | 2018-10-30 | ||
| 2018-10-30 holding as of filing | Dearen Danny L. Officer (See Remarks) | 3 | Stock Option (Right to Buy) Derivative · Direct | Holding | $0.98 exercise price | 2018-10-30 | ||
| 2018-10-30 holding as of filing | Dearen Danny L. Officer (See Remarks) | 3 | Stock Option (Right to Buy) Derivative · Direct | Holding | $1.32 exercise price | 2018-10-30 | ||
| 2018-10-30 holding as of filing | Dearen Danny L. Officer (See Remarks) | 3 | Stock Option (Right to Buy) Derivative · Direct | Holding | $1.32 exercise price | 2018-10-30 | ||
| 2018-10-30 holding as of filing | Dearen Danny L. Officer (See Remarks) | 3 | Stock Option (Right to Buy) Derivative · Direct | Holding | $1.42 exercise price | 2018-10-30 | ||
| 2018-10-30 holding as of filing | Dearen Danny L. Officer (See Remarks) | 3 | Stock Option (Right to Buy) Derivative · Direct | Holding | $1.63 exercise price | 2018-10-30 | ||
| 2018-10-30 holding as of filing | Woock John Officer (Chief Marketing Officer) | 3 | Stock Option (Right to Buy) Derivative · Direct | Holding | $1.32 exercise price | 2018-10-30 | ||
| 2018-10-30 holding as of filing | Woock John Officer (Chief Marketing Officer) | 3 | Stock Option (Right to Buy) Derivative · Direct | Holding | $1.42 exercise price | 2018-10-30 | ||
| 2018-10-30 holding as of filing | Woock John Officer (Chief Marketing Officer) | 3 | Stock Option (Right to Buy) Derivative · Direct | Holding | $1.63 exercise price | 2018-10-30 | ||
| 2018-10-30 holding as of filing | Sama Rinda Officer (Chief Operating Officer) | 3 | Stock Option (Right to Buy) Derivative · Direct | Holding | $1.63 exercise price | 2018-10-30 | ||
| 2018-10-30 holding as of filing | Williamson Michael V. Officer (See Remarks) | 3 | Stock Option (Right to Buy) Derivative · Direct | Holding | $1.32 exercise price | 2018-10-30 | ||
| 2018-10-30 holding as of filing | Williamson Michael V. Officer (See Remarks) | 3 | Stock Option (Right to Buy) Derivative · Direct | Holding | $1.32 exercise price | 2018-10-30 | ||
| 2018-10-30 holding as of filing | Williamson Michael V. Officer (See Remarks) | 3 | Stock Option (Right to Buy) Derivative · Direct | Holding | $1.42 exercise price | 2018-10-30 | ||
| 2018-10-30 holding as of filing | Williamson Michael V. Officer (See Remarks) | 3 | Stock Option (Right to Buy) Derivative · Direct | Holding | $1.63 exercise price | 2018-10-30 | ||
| 2018-10-30 holding as of filing | Noblett Karen Officer (Chief Medical Officer) | 3 | Stock Option (Right to Buy) Derivative · Direct | Holding | $0.97 exercise price | 2018-10-30 | ||
| 2018-10-30 holding as of filing | Noblett Karen Officer (Chief Medical Officer) | 3 | Stock Option (Right to Buy) Derivative · Direct | Holding | $0.98 exercise price | 2018-10-30 | ||
| 2018-10-30 holding as of filing | Noblett Karen Officer (Chief Medical Officer) | 3 | Stock Option (Right to Buy) Derivative · Direct | Holding | $1.32 exercise price | 2018-10-30 | ||
| 2018-10-30 holding as of filing | Noblett Karen Officer (Chief Medical Officer) | 3 | Stock Option (Right to Buy) Derivative · Direct | Holding | $1.32 exercise price | 2018-10-30 | ||
| 2018-10-30 holding as of filing | Noblett Karen Officer (Chief Medical Officer) | 3 | Stock Option (Right to Buy) Derivative · Direct | Holding | $1.42 exercise price | 2018-10-30 | ||
| 2018-10-30 holding as of filing | Noblett Karen Officer (Chief Medical Officer) | 3 | Stock Option (Right to Buy) Derivative · Direct | Holding | $1.63 exercise price | 2018-10-30 | ||
| 2018-10-30 holding as of filing | MATHUR PRABODH Officer (See Remarks) | 3 | Stock Option (Right to Buy) Derivative · Direct | Holding | $1.63 exercise price | 2018-10-30 | ||
| 2018-10-30 holding as of filing | COHEN RAYMOND W Director, Officer (Chief Executive Officer) | 3 | Stock Option (Right to Buy) Derivative · Direct · (m) | Holding | $1.63 exercise price | 2018-10-30 |